259 related articles for article (PubMed ID: 15906176)
1. Comparison of molecular mobility in the glassy state between amorphous indomethacin and salicin based on spin-lattice relaxation times.
Masuda K; Tabata S; Sakata Y; Hayase T; Yonemochi E; Terada K
Pharm Res; 2005 May; 22(5):797-805. PubMed ID: 15906176
[TBL] [Abstract][Full Text] [Related]
2. Relaxation behaviour of D(-)-salicin as studied by Thermally Stimulated Depolarisation Currents (TSDC) and Differential Scanning Calorimetry (DSC).
Diogo HP; Pinto SS; Moura Ramos JJ
Int J Pharm; 2008 Jun; 358(1-2):192-7. PubMed ID: 18417303
[TBL] [Abstract][Full Text] [Related]
3. Correlation between Molecular Mobility and Physical Stability in Pharmaceutical Glasses.
Mehta M; Ragoonanan V; McKenna GB; Suryanarayanan R
Mol Pharm; 2016 Apr; 13(4):1267-77. PubMed ID: 26895136
[TBL] [Abstract][Full Text] [Related]
4. Predictions of onset of crystallization from experimental relaxation times I-correlation of molecular mobility from temperatures above the glass transition to temperatures below the glass transition.
Bhugra C; Shmeis R; Krill SL; Pikal MJ
Pharm Res; 2006 Oct; 23(10):2277-90. PubMed ID: 16933094
[TBL] [Abstract][Full Text] [Related]
5. Milling-induced disorder of pharmaceuticals: one-phase or two-phase system?
Luisi BS; Medek A; Liu Z; Mudunuri P; Moulton B
J Pharm Sci; 2012 Apr; 101(4):1475-85. PubMed ID: 22213593
[TBL] [Abstract][Full Text] [Related]
6. Prediction of the onset of crystallization of amorphous sucrose below the calorimetric glass transition temperature from correlations with mobility.
Bhugra C; Rambhatla S; Bakri A; Duddu SP; Miller DP; Pikal MJ; Lechuga-Ballesteros D
J Pharm Sci; 2007 May; 96(5):1258-69. PubMed ID: 17455303
[TBL] [Abstract][Full Text] [Related]
7. Relationship between the crystallization rates of amorphous nifedipine, phenobarbital, and flopropione, and their molecular mobility as measured by their enthalpy relaxation and (1)H NMR relaxation times.
Aso Y; Yoshioka S; Kojima S
J Pharm Sci; 2000 Mar; 89(3):408-16. PubMed ID: 10707020
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of the amorphous and crystalline alpha-, gamma-phases of indomethacin.
Carpentier L; Decressain R; Desprez S; Descamps M
J Phys Chem B; 2006 Jan; 110(1):457-64. PubMed ID: 16471556
[TBL] [Abstract][Full Text] [Related]
9. Microscopic molecular mobility of amorphous AG-041R measured by solid-state 13C NMR.
Koga A; Yonemochi E; Machida M; Aso Y; Ushio H; Terada K
Int J Pharm; 2004 May; 275(1-2):73-83. PubMed ID: 15081139
[TBL] [Abstract][Full Text] [Related]
10. Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures.
Hancock BC; Shamblin SL; Zografi G
Pharm Res; 1995 Jun; 12(6):799-806. PubMed ID: 7667182
[TBL] [Abstract][Full Text] [Related]
11. Explanation of the crystallization rate of amorphous nifedipine and phenobarbital from their molecular mobility as measured by (13)C nuclear magnetic resonance relaxation time and the relaxation time obtained from the heating rate dependence of the glass transition temperature.
Aso Y; Yoshioka S; Kojima S
J Pharm Sci; 2001 Jun; 90(6):798-806. PubMed ID: 11357180
[TBL] [Abstract][Full Text] [Related]
12. Crystallization of indomethacin from the amorphous state below and above its glass transition temperature.
Yoshioka M; Hancock BC; Zografi G
J Pharm Sci; 1994 Dec; 83(12):1700-5. PubMed ID: 7891297
[TBL] [Abstract][Full Text] [Related]
13. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance.
Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M
J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651
[TBL] [Abstract][Full Text] [Related]
14. Investigation of physical properties and stability of indomethacin-cimetidine and naproxen-cimetidine co-amorphous systems prepared by quench cooling, coprecipitation and ball milling.
Lim AW; Löbmann K; Grohganz H; Rades T; Chieng N
J Pharm Pharmacol; 2016 Jan; 68(1):36-45. PubMed ID: 26663364
[TBL] [Abstract][Full Text] [Related]
15. Prediction of onset of crystallization from experimental relaxation times. II. Comparison between predicted and experimental onset times.
Bhugra C; Shmeis R; Krill SL; Pikal MJ
J Pharm Sci; 2008 Jan; 97(1):455-72. PubMed ID: 17854050
[TBL] [Abstract][Full Text] [Related]
16. Solid-State NMR Investigation of Drug-Excipient Interactions and Phase Behavior in Indomethacin-Eudragit E Amorphous Solid Dispersions.
Lubach JW; Hau J
Pharm Res; 2018 Feb; 35(3):65. PubMed ID: 29464409
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of indomethacin and nifedipine using variable-temperature solid-state NMR.
Apperley DC; Forster AH; Fournier R; Harris RK; Hodgkinson P; Lancaster RW; Rades T
Magn Reson Chem; 2005 Nov; 43(11):881-92. PubMed ID: 16059964
[TBL] [Abstract][Full Text] [Related]
18. Glass transition-related changes in molecular mobility below glass transition temperature of freeze-dried formulations, as measured by dielectric spectroscopy and solid state nuclear magnetic resonance.
Yoshioka S; Aso Y
J Pharm Sci; 2005 Feb; 94(2):275-87. PubMed ID: 15570601
[TBL] [Abstract][Full Text] [Related]
19. Molecular mobility of nifedipine-PVP and phenobarbital-PVP solid dispersions as measured by 13C-NMR spin-lattice relaxation time.
Aso Y; Yoshioka S
J Pharm Sci; 2006 Feb; 95(2):318-25. PubMed ID: 16372315
[TBL] [Abstract][Full Text] [Related]
20. Calorimetric study and modeling of molecular mobility in amorphous organic pharmaceutical compounds using a modified Adam-Gibbs approach.
Mao C; Chamarthy SP; Pinal R
J Phys Chem B; 2007 Nov; 111(46):13243-52. PubMed ID: 17967007
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
